Abstract:Introduction: Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Due to its complexity, it has been hard to find an ideal medicine to treat all cancer types, although there is an urgent need for it. However, the cost of developing a new drug is high and time-consuming. In this sense, drug repurposing (DR) can hasten drug discovery by giving existing drugs new disease indications. Many computational methods have been applied to achieve DR, but just a few have succeeded. Therefore, this review aims to show in silico DR approaches and the gap between these strategies and their ultimate application in oncology. Methods: The scoping review was conducted according to the Arksey and O'Malley framework and the Joanna Briggs Institute recommendations. Relevant studies were identified through electronic searching of PubMed/MEDLINE, Embase, Scopus, and Web of Science databases, as well as the grey literature. We included peer-reviewed research articles involving in silico strategies applied to drug repurposing in oncology, published between 1 January 2003, and 31 December 2021. Results: We identified 238 studies for inclusion in the review. Most studies revealed that the United States, India, China, South Korea, and Italy are top publishers. Regarding cancer types, breast cancer, lymphomas and leukemias, lung, colorectal, and prostate cancer are the top investigated. Additionally, most studies solely used computational methods, and just a few assessed more complex scientific models. Lastly, molecular modeling, which includes molecular docking and molecular dynamics simulations, was the most frequently used method, followed by signature-, Machine Learning-, and network-based strategies. Discussion: DR is a trending opportunity but still demands extensive testing to ensure its safety and efficacy for the new indications. Finally, implementing DR can be challenging due to various factors, including lack of quality data, patient populations, cost, intellectual property issues, market considerations, and regulatory requirements. Despite all the hurdles, DR remains an exciting strategy for identifying new treatments for numerous diseases, including cancer types, and giving patients faster access to new medications.

Computational drug repurposing based on electronic health records: a scoping review

An Analytical Review of Computational Drug Repurposing

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Application of artificial intelligence and machine learning in drug repurposing

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.

Drug Repurposing: An Effective Tool in Modern Drug Discovery

Repurposing of Drugs: Updates and New Perspectives

Artificial intelligence, machine learning, and drug repurposing in cancer

Drug repositioning: A bibliometric analysis

Exploring NCATS in-house biomedical data for evidence-based drug repurposing

In silico approaches for drug repurposing in oncology: a scoping review

Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database

Drug repurposing: a systematic review on root causes, barriers and facilitators

Artificial intelligence in COVID-19 drug repurposing

Drug discovery and development: the role of artificial intelligence in drug repurposing

Artificial Intelligence-based Efficacy Prediction of Phase 3 Clinical Trial for Repurposing Heart Failure Therapies

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph